Literature DB >> 28797191

Systematic review seeking erythropoietin role for neuroprotection in neonates with hypoxic ischemic encephalopathy: presently where do we stand.

Bhawandeep Garg1, Deepak Sharma2, Anju Bansal3.   

Abstract

BACKGROUND: Hypoxic ischemic encephalopathy (HIE) is one of the leading causes of neonatal mortality in developing countries and leads to some form of neuro-developmental disability in latter part of life. AIMS: The aim of this study is to evaluate the role of erythropoietin (EPO) in neuroprotection for term newborn having HIE.
METHOD: The literature search was done for various trials by searching the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, EMBASE, Web of science, Scopus, Index Copernicus, and other database.
RESULTS: A total of nine studies fulfilled inclusion criteria. EPO has shown to cause reduction in death and disability, better long-term neuro-developmental outcome, improvement in EEG, and reduction in risk of cerebral palsy.
CONCLUSION: EPO treatment has neuroprotective effects against moderate/severe HIE and improves long-term behavioral neurological developments in neonates.

Entities:  

Keywords:  Erythropoietin; hypoxic ischemic encephalopathy; neuro-development

Mesh:

Substances:

Year:  2017        PMID: 28797191     DOI: 10.1080/14767058.2017.1366982

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  9 in total

1.  High-Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL): A Randomized Controlled Trial - Background, Aims, and Study Protocol.

Authors:  Sandra E Juul; Bryan A Comstock; Patrick J Heagerty; Dennis E Mayock; Amy M Goodman; Stephanie Hauge; Fernando Gonzalez; Yvonne W Wu
Journal:  Neonatology       Date:  2018-03-07       Impact factor: 4.035

2.  Perinatal Anemia is Associated with Neonatal and Neurodevelopmental Outcomes in Infants with Moderate to Severe Perinatal Asphyxia.

Authors:  Willemien S Kalteren; Hendrik J Ter Horst; Anne E den Heijer; Leanne de Vetten; Elisabeth M W Kooi; Arend F Bos
Journal:  Neonatology       Date:  2018-07-19       Impact factor: 4.035

3.  Erythropoietin protects neurons from apoptosis via activating PI3K/AKT and inhibiting Erk1/2 signaling pathway.

Authors:  Wei Si; Jianyi Wang; Mei Li; Hao Qu; Ran Gu; Rui Liu; Lu Wang; Shirong Li; Xiao Hu
Journal:  3 Biotech       Date:  2019-03-07       Impact factor: 2.406

Review 4.  Free radicals and neonatal encephalopathy: mechanisms of injury, biomarkers, and antioxidant treatment perspectives.

Authors:  Silvia Martini; Topun Austin; Arianna Aceti; Giacomo Faldella; Luigi Corvaglia
Journal:  Pediatr Res       Date:  2019-10-26       Impact factor: 3.756

Review 5.  Perinatal hypoxic-ischemic damage: review of the current treatment possibilities.

Authors:  A Frajewicki; Z Laštůvka; V Borbélyová; S Khan; K Jandová; K Janišová; J Otáhal; J Mysliveček; V Riljak
Journal:  Physiol Res       Date:  2020-12-31       Impact factor: 1.881

Review 6.  Pharmacokinetics during therapeutic hypothermia for neonatal hypoxic ischaemic encephalopathy: a literature review.

Authors:  Isabelle Claire Lutz; Karel Allegaert; Jan N de Hoon; Heleen Marynissen
Journal:  BMJ Paediatr Open       Date:  2020-06-15

7.  Impact of Erythropoietin in the management of Hypoxic Ischaemic Encephalopathy in resource-constrained settings: protocol for a randomized control trial.

Authors:  Beatrice Ezenwa; Chinyere Ezeaka; Iretiola Fajolu; Anne Ogbenna; Omodele Olowoyeye; Obiyo Nwaiwu; Zainab Opoola; Gbenga Olorunfemi
Journal:  BMC Neurol       Date:  2020-05-04       Impact factor: 2.474

8.  Efficacy of erythropoietin alone in treatment of neonates with hypoxic-ischemic encephalopathy: A protocol for systematic review and meta-analysis.

Authors:  Guang Yang; Zhimin Xue; Yuan Zhao
Journal:  Medicine (Baltimore)       Date:  2021-06-18       Impact factor: 1.817

Review 9.  Treatment of Neonatal Hypoxic-Ischemic Encephalopathy with Erythropoietin Alone, and Erythropoietin Combined with Hypothermia: History, Current Status, and Future Research.

Authors:  Dorothy E Oorschot; Rachel J Sizemore; Ashraf R Amer
Journal:  Int J Mol Sci       Date:  2020-02-21       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.